<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00416832</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000514355</org_study_id>
    <secondary_id>GPOH-HD-2002</secondary_id>
    <secondary_id>EU-20651</secondary_id>
    <nct_id>NCT00416832</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Hodgkin's Lymphoma</brief_title>
  <official_title>Optimising Therapy for Boys With Hodgkin's Lymphoma and Quality Assurance of Therapy for Girls With Hodgkin's Lymphoma Until Start of a New Prospective Trial for Hodgkin's Lymphoma in Childhood and Adolescence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Christine Mauz-Körholz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Martin-Luther-Universität Halle-Wittenberg</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer&#xD;
      cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses&#xD;
      high-energy x-rays to kill cancer cells. Giving combination chemotherapy together with&#xD;
      radiation therapy may kill more cancer cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying the side effects and how well giving combination&#xD;
      chemotherapy together with radiation therapy works in treating young patients with Hodgkin's&#xD;
      lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the safety and efficacy of intensified etoposide administered as a part of&#xD;
           OEPA combination chemotherapy (vincristine, etoposide, prednisone, and doxorubicin&#xD;
           hydrochloride) in pediatric male patients with intermediate or advanced Hodgkin's&#xD;
           lymphoma (HL).&#xD;
&#xD;
        -  Determine the safety and efficacy of COPDIC combination chemotherapy (cyclophosphamide,&#xD;
           vincristine, prednisone, and dacarbazine) or COPP combination chemotherapy&#xD;
           (cyclophosphamide, vincristine, procarbazine hydrochloride, and prednisone) in reducing&#xD;
           gonadotoxicity in male or female patients.&#xD;
&#xD;
        -  Assess quality assurance of these regimens in pediatric female patients with&#xD;
           intermediate or advanced HL.&#xD;
&#xD;
      OUTLINE: This is a pilot, multicenter study. Patients are stratified according to disease&#xD;
      stage (I or IIA vs IIB, IIE, or IIIA vs IIBE, IIIBE, or IV).&#xD;
&#xD;
        -  Stratum 1 (stages I or IIA): Male patients receive vincristine IV on days 1, 8, and 15,&#xD;
           etoposide IV over 2 hours on days 3-7, oral prednisone on days 1-15, and doxorubicin&#xD;
           hydrochloride IV over 4 hours on days 1 and 15 (OEPA). Female patients receive&#xD;
           vincristine, prednisone, and doxorubicin hydrochloride as in male patients and oral&#xD;
           procarbazine hydrochloride on days 1-15 (OPPA). Both regimens repeat every 4 weeks for 2&#xD;
           courses in the absence of disease progression or unacceptable toxicity. Patients who do&#xD;
           not achieve complete remission undergo involved-field radiotherapy beginning 3 weeks&#xD;
           after completion of chemotherapy.&#xD;
&#xD;
        -  Stratum 2 (stages IIB, IIE, or IIIA): Male patients receive 2 courses of OEPA as in&#xD;
           stratum 1 followed by 2 courses of COPDIC comprising oral prednisone on days 1-15,&#xD;
           dacarbazine IV over 30 minutes on days 1-3, and vincristine IV and cyclophosphamide IV&#xD;
           over 1 hour on days 1 and 8. Female patients receive 2 courses of OPPA as in stratum 1&#xD;
           followed by COPP comprising oral prednisone and 2 courses of oral procarbazine&#xD;
           hydrochloride on days 1-15 and vincristine IV and cyclophosphamide IV over 1 hour on&#xD;
           days 1 and 8. Both regimens repeat every 4 weeks for 2 courses in the absence of disease&#xD;
           progression or unacceptable toxicity. Beginning 3 weeks after completion of&#xD;
           chemotherapy, all patients undergo involved-field radiotherapy.&#xD;
&#xD;
        -  Stratum 3 (stages IIBE, IIIBE, or IV): Male patients receive 2 courses of OEPA as in&#xD;
           stratum 1 followed by 4 courses of COPDIC as in stratum 2. Female patients receive 2&#xD;
           courses of OPPA as in stratum 1 followed by 4 courses of COPP as in stratum 2. Beginning&#xD;
           3 weeks after completion of chemotherapy, all patients undergo involved-field&#xD;
           radiotherapy.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 648 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2002</start_date>
  <completion_date type="Actual">December 2005</completion_date>
  <primary_completion_date type="Actual">December 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and efficacy</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Reduction of gonadotoxicity</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality assurance</measure>
  </primary_outcome>
  <enrollment type="Anticipated">648</enrollment>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dacarbazine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>procarbazine hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine sulfate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of classic Hodgkin's lymphoma (HL)&#xD;
&#xD;
               -  Intermediate or advanced disease, including the following stages:&#xD;
&#xD;
                    -  Stage I&#xD;
&#xD;
                    -  Stage IIA, IIB, IIE, or IIBE&#xD;
&#xD;
                    -  Stage IIIA or IIIBE&#xD;
&#xD;
                    -  Stage IV&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  No other concurrent malignancies&#xD;
&#xD;
          -  No severe concurrent diseases (e.g., immune deficiency syndrome)&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No prior chemotherapy or radiotherapy&#xD;
&#xD;
          -  Pre-phase therapy for large mediastinal tumor allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dieter Koerholz, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Martin-Luther-Universität Halle-Wittenberg</affiliation>
  </overall_official>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>December 27, 2006</study_first_submitted>
  <study_first_submitted_qc>December 27, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 28, 2006</study_first_posted>
  <last_update_submitted>March 24, 2020</last_update_submitted>
  <last_update_submitted_qc>March 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Martin-Luther-Universität Halle-Wittenberg</investigator_affiliation>
    <investigator_full_name>Christine Mauz-Körholz</investigator_full_name>
    <investigator_title>Prof. Dr. Christine Mauz-Körholz</investigator_title>
  </responsible_party>
  <keyword>stage II childhood Hodgkin lymphoma</keyword>
  <keyword>stage III childhood Hodgkin lymphoma</keyword>
  <keyword>stage IV childhood Hodgkin lymphoma</keyword>
  <keyword>stage I childhood Hodgkin lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Dacarbazine</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Procarbazine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

